|
|
Volumn 22, Issue 12, 2004, Pages 1513-1519
|
|
Recombinant protein therapeutics - Success rates, market trends and values to 2010
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ALEFACEPT;
ALPHA INTERFERON;
ANTIINFECTIVE AGENT;
ANTINEOPLASTIC AGENT;
ANTIVIRUS AGENT;
BETA INTERFERON;
BETA1A INTERFERON;
BLOOD CLOTTING FACTOR;
CALCITONIN;
CYTOKINE;
DENILEUKIN DIFTITOX;
EFALIZUMAB;
ETANERCEPT;
FIBRINOLYTIC AGENT;
GAMMA INTERFERON;
GLATIRAMER;
HUMAN GROWTH HORMONE;
HUMAN INSULIN;
INFLIXIMAB;
INSULIN;
INSULIN DETEMIR;
INSULIN GLARGINE;
INSULIN GLULISINE;
INTERFERON;
INTERLEUKIN 1;
INTERLEUKIN 2;
INTERLEUKIN 4;
INTERLEUKIN DERIVATIVE;
KERATINOCYTE GROWTH FACTOR;
LATUS;
NESIRITIDE;
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
PEGINTERFERON ALPHA2B;
RECOMBINANT ERYTHROPOIETIN;
RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
RECOMBINANT LUTEINIZING HORMONE;
RECOMBINANT PROTEIN;
RIBOSOME DNA;
SOMATOMEDIN;
UNINDEXED DRUG;
BIOTECHNOLOGY;
CLINICAL STUDY;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG INDICATION;
DRUG MARKETING;
FOOD AND DRUG ADMINISTRATION;
FORECASTING;
HISTORY;
HUMAN;
PATENT;
PRIORITY JOURNAL;
REVIEW;
CLINICAL TRIALS;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG THERAPY;
FORECASTING;
INTERNATIONALITY;
MARKETING;
MODELS, ECONOMETRIC;
PHARMACEUTICAL PREPARATIONS;
RECOMBINANT PROTEINS;
UNITED STATES;
|
|
EID: 11144334098
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/nbt1204-1513 Document Type: Review |
|
Times cited : (272)
|
|
References (5)
|
